Hematopoietic stem cell transplantation disrupts age-related gut microbiota signatures in pediatric and adult recipients - Takeaways - MDSpire

Hematopoietic stem cell transplantation disrupts age-related gut microbiota signatures in pediatric and adult recipients

  • By

  • Davide Leardini

  • Marcello Roberto

  • Sara Roggiani

  • Edoardo Muratore

  • Marco Fabbrini

  • Gianluca Storci

  • Enrica Tomassini

  • Elisa Dan

  • Angela Schipani

  • Serena De Matteis

  • Barbara Sinigaglia

  • Daria Messelodi

  • Nicola Salvatore Bertuccio

  • Arcangelo Prete

  • Patrizia Brigidi

  • Francesca Bonifazi

  • Riccardo Masetti

  • September 25, 2025

  • 0 min

Share

  • 1

    Hematopoietic stem cell transplantation (HSCT) alters gut microbiota diversity and composition in both pediatric and adult recipients.

  • 2

    Higher alpha diversity in gut microbiota before HSCT correlates with improved overall survival and reduced graft-versus-host disease (GvHD) in adults.

  • 3

    Pediatric gut microbiota shows greater variability and disruption post-HSCT compared to adults, complicating outcome predictions.

  • 4

    Age-related differences in gut microbiota composition impact post-HSCT microbial dynamics and clinical outcomes.

  • 5

    The study aims to analyze gut microbiota changes across age groups to understand their influence on post-HSCT outcomes.

Original Source(s)

Hematopoietic stem cell transplantation disrupts age-related gut microbiota signatures in pediatric and adult recipients

  • by Davide Leardini, Marcello Roberto, Sara Roggiani, Edoardo Muratore, Marco Fabbrini, Gianluca Storci, Enrica Tomassini, Elisa Dan, Angela Schipani, Serena De Matteis, Barbara Sinigaglia, Daria Messelodi, Nicola Salvatore Bertuccio, Arcangelo Prete, Patrizia Brigidi, Francesca Bonifazi, Riccardo Masetti

  • September 25, 2025

Related Content

Liver involvement in pediatric acute leukemia: subtype differences and complex hepatic injury as a novel marker for AML risk stratification

Intravenous Administration of Zoledronate in Children with Bone-Associated Langerhans Cell Histiocytosis

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, ADAMTS13. Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved product for management of cTTP. This article reviews the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and implications for advanced practitioners of rADAMTS13.